Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
=== Genetics === People can also develop CJD because they carry a mutation of the gene that codes for the prion protein (PRNP), located on chromosome 202p12-pter. This occurs in only 10–15% of all CJD cases. In sporadic cases, the misfolding of the prion protein is a process that is hypothesized to occur as a result of the effects of aging on cellular machinery, explaining why the disease often appears later in life. An EU study determined that "87% of cases were sporadic, 8% genetic, 5% iatrogenic and less than 1% variant."
== Employment == Biochemists are typically employed in the life sciences, where they work in the pharmaceutical or biotechnology industry in a research role. They are also employed in academic institutes, where in addition to pursuing their research, they may also be involved with teaching undergraduates, training graduate students, and collaborating with post-doctoral fellows. Because of a biochemists' background in both biology and chemistry, they may also be employed in the medical, industrial, governmental, and environmental fields. Slightly more than half of the biological scientists are employed by the Federal State and local governments. The field of medicine includes nutrition, genetics, biophysics, and pharmacology; industry includes beverage and food technology, toxicology, and vaccine production; while the governmental and environmental fields includes forensic science, wildlife management, marine biology, and viticulture. The average income of a biochemist was $82,150 in 2017. The range of the salaries begin around 44,640 to 153,810, reported in 2017. The United States Federal Government in 2005 reported the average salaries in different fields associated with biochemistry and being a biochemist. General biological scientists in nonsupervisory, supervisory, and managerial positions earned an average salary of $69,908; microbiologists, $80,798; ecologists, $72,021; physiologists, $93,208; geneticists, $85,170; zoologists, $101,601; and botanists, $62,207.
== Pathology == Tuftsin deficiency can be hereditary or can occur following splenectomy, resulting in increased susceptibility to certain diseases e.g.: infected eczematous dermatitis with draining lymph nodes, otitis and sinusitis. Acquired tuftsin deficiency can occur in granulocyte leukemia, when blood neutrophils failed to show stimulation with synthetic tuftsin or with the serum leukokinin. Serum level of tuftsin was minimal or absent.
Sources: en.wikipedia.org
The 43-second "Iron Gland" was developed out of a guitar riff that Cantrell would play that annoyed the other band members, so he created the song (adding in a reference to Black Sabbath's "Iron Man") and promised to never play the guitar riff again. It features Tom Araya of thrash metal band Slayer on vocals, as well as Layne Staley. "Hate to Feel" and "Angry Chair" were both composed solely by Staley, who also played guitar on both tracks, and Cantrell has expressed his pride in seeing Staley grow as a songwriter and guitarist. "Down in a Hole" was written by Cantrell to his long-time girlfriend, Courtney Clarke. Cantrell explained the song in the liner notes of 1999's Music Bank box set: "["Down in a Hole"]'s in my top three, personally. It's to my long-time love. It's the reality of my life, the path I've chosen and in a weird way it kind of foretold where we are right now. It's hard for us to both understand... that this life is not conducive to much success with long-term relationships." The album's final track, "Would?", was written by Cantrell as a tribute to his friend and late lead singer of Mother Love Bone, Andrew Wood, who died of a drug overdose in 1990. Cantrell said the song is also "directed towards people who pass judgments."
Commensal bacteria contribute to immune maturation, maintenance of epithelial barrier function, and induction of tolerogenic immune responses. Reduced microbial diversity and loss of certain bacterial taxa may impair oral tolerance and promote allergic sensitization. Short-chain fatty acids produced by intestinal bacteria may further support regulatory immune pathways and intestinal barrier integrity. Sensitization to food allergens may also occur through non-oral routes. Exposure to allergens through damaged skin, particularly in individuals with impaired skin barriers such as those with atopic dermatitis, may predispose to food allergy if oral tolerance has not yet been established. This has contributed to the hypothesis that the timing, route, and context of allergen exposure influence whether tolerance or allergic sensitization develops. Research into gastrointestinal immune mechanisms has influenced preventive approaches to food allergy. Early introduction of allergenic foods, including peanuts and eggs, during infancy has been associated in some populations with a reduced risk of food allergy, likely by promoting oral tolerance during critical periods of immune development.
The ending isotope of this chain is now known to be thallium-205. Some older sources give the final isotope as bismuth-209, but in 2003 it was discovered that it is very slightly radioactive, with a half-life of 2.01×1019 years. There are also non-transuranic decay chains of unstable isotopes of light elements, for example those of magnesium-28 and chlorine-39. On Earth, most of the starting isotopes of these chains before 1945 were generated by cosmic radiation. Since 1945, the testing and use of nuclear weapons has also released numerous radioactive fission products. Almost all such isotopes decay by either β− or β+ decay modes, changing from one element to another at the same atomic mass. The later daughter products in such a chain, being closer to beta-stability, generally have the longer half-lives.
== External links == "Gonadotrophin-Releasing Hormone Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-04. GNRHR+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.